The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure
Abstract
BACKGROUND: Even with optimal pharmacotherapy, symptomatic heart failure is associated with substantial morbidity and mortality. PURPOSE: To determine the efficacy and safety of cardiac resynchronization therapy in adults with advanced systolic heart failure. DATA SOURCES: The Cochrane Central Register of Controlled Trials (2002, volume 4), MEDLINE (1980-2003), EMBASE (1980-2003), other electronic databases, and U.S. Food and Drug Administration reports. We contacted primary study authors and device manufacturers, and we hand searched bibliographies of relevant papers and conference proceedings. STUDY SELECTION: Randomized, controlled clinical trials for efficacy and controlled trials plus prospective cohort studies for safety. DATA EXTRACTION: Two reviewers chose studies and extracted data independently; random-effects models were used for analyses. DATA SYNTHESIS: Nine trials were included in the efficacy review (3216 patients). All trial participants had reduced ejection fraction and prolonged QRS duration, and 85% had New York Heart Association (NYHA) class III or IV symptoms. Cardiac resynchronization therapy improved ejection fraction (weighted mean difference, 0.035 [95% CI, 0.015 to 0.055]), quality of life (weighted mean reduction in score on the Minnesota Living with Heart Failure Questionnaire, 7.6 points [CI, 3.8 to 11.5 points]), and function (58% vs. 37% of patients improved by at least 1 NYHA class). Heart failure hospitalizations were reduced by 32% (relative risk [RR], 0.68 [CI, 0.41 to 1.12]), with benefits most marked in patients with NYHA class III or IV symptoms at baseline (RR, 0.65 [CI, 0.48 to 0.88]; number needed to treat for benefit [NNT(B)], 12). All-cause mortality was reduced by 21% (RR, 0.79 [CI, 0.66 to 0.96]; NNT(B), 24), driven largely by reductions in death from progressive heart failure (RR, 0.60 [CI, 0.36 to 1.01]). Eighteen studies (total of 3701 patients with cardiac resynchronization devices) were included in the safety review. Implant success rate was 90% (CI, 89% to 91%), and 0.4% of patients died during implantation (CI, 0.2% to 0.7%). Over a median 6-month follow-up, leads dislodged in 9% of patients (CI, 7% to 10%) and mechanical malfunctions occurred in 7% (CI, 5% to 8%). LIMITATIONS: These trials enrolled only patients with heart failure with NYHA class III or IV symptoms despite medical therapy, a prolonged QRS duration, and reduced ejection fraction; in addition, experienced providers implanted the devices. Because all but one of these trials randomly assigned patients after device implantation, their results may overestimate the potential benefits of cardiac resynchronization. Finally, since few patients in these trials had bradyarrhythmias or atrial fibrillation, the role of cardiac resynchronization in such patients is uncertain. CONCLUSIONS: In selected patients with heart failure, cardiac resynchronization therapy improves functional and hemodynamic status, reduces heart failure hospitalizations, and reduces all-cause mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Bristow, M. R., Saxon, L. A., Boehmer, J., Krueger, S., Kass, D. A., De Marco, T., Carson, P., DiCarlo, L., DeMets, D., White, B. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032423 · Cited by 5,812
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Cardiac Resynchronization in Chronic Heart Failure
Abraham, W. T., Fisher, W. G., Smith, A. L., Delurgio, D. B., Leon, A. R., Loh, E., Kocovic, D. Z., Packer, M., Clavell, A. L., Hayes, D. L., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013168 · Cited by 4,648
Self-citationCARDIAC RESYNCHRONIZATION IN CHRONIC HEART FAILURE
Braham, W. I. T. A., Isher, W. E. G. F., Mith, L. S., Elurgio, D. A. B. D., Eon, A. N. R. L., Oh, E., Ocovic, D. U. Z. K., Acker, M. G., Lavell, L. C., Ayes, D. A. L. H., et al. (2002) · Cited by 3,808
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Cazeau, S., Leclercq, C., Lavergne, T., Walker, S., Varma, C., Linde, C., Garrigue, S., Kappenberger, L., Haywood, G. A., Santini, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441202 · Cited by 2,751
Young, J. B., Abraham, W. T., & Smith, A. L. (2003) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.08.087 · Cited by 1,682
Self-citationLifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study
Lloyd-Jones, D. M., Larson, M. G., Leip, E. P., Beiser, A., D’Agostino, R. B., Kannel, W. B., Murabito, J. M., Vasan, R. S., Benjamin, E. J., & Levy, D. (2002) · Circulation · doi:10.1161/01.cir.0000039105.49749.6f · Cited by 1,613
Cited by
The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure
Cleland, J. G. F., Daubert, J.-C., Erdmann, E., Freemantle, N., Gras, D., Kappenberger, L., & Tavazzi, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050496 · Cited by 6,276
The Seattle Heart Failure Model: Prediction of Survival in Heart Failure
Levy, W. C., Mozaffarian, D., Linker, D. T., Sutradhar, S. C., Anker, S. D., Cropp, A. B., Anand, I., Maggioni, A., Burton, P., Sullivan, M. D., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.584102 · Cited by 2,021
Authors/Task Force Members, Vardas, P. E., Auricchio, A., Blanc, J.-J., Daubert, J.-C., Drexler, H., Ector, H., Gasparini, M., Linde, C., Morgado, F. B., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm305 · Cited by 902
McMurray, J. J., & Pfeffer, M. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66621-4 · Cited by 831
2010 Focused Update of ESC Guidelines on device therapy in heart failure
Authors/Task Force Members, Dickstein, K., Vardas, P. E., Auricchio, A., Daubert, J.-C., Linde, C., McMurray, J., Ponikowski, P., Priori, S. G., Sutton, R., et al. (2010) · EP Europace · doi:10.1093/europace/euq392 · Cited by 593
Metadata
- Authors
- McAlister, F. A., Ezekowitz, J. A., Wiebe, N., Rowe, B., Spooner, C., Crumley, E., Hartling, L., Klassen, T., & Abraham, W.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2004-09-07
- Volume
- 141
- Issue
- 5
- Pages
- 381-390
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2102342133
- Cited by
- 315
- References
- 45
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure. https://app.cochat.ai/papers/10.7326/0003-4819-141-5-200409070-00101
- The paper
- McAlister, F. A., Ezekowitz, J. A., Wiebe, N., Rowe, B., Spooner, C., Crumley, E., Hartling, L., Klassen, T., & Abraham, W. (2004). Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-141-5-200409070-00101
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.